<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0305233584
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NUBEQA
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DAROLUTAMIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        112
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        10502.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Orion Corporation, Orion Pharma" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Orion Corporation, Orion Pharma
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2947]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Bayer Saudi Arabia
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        L02BB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>NUBEQA contains the active substance darolutamide.</p><p>It is used to treat <strong>adult men with prostate cancer</strong> that:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has not spread to other parts of the body and no longer responds to medical or surgical treatment that lowers testosterone (also called non-metastatic castration‑resistant prostate cancer)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has spread to other parts of the body and responds to medical or surgical treatment that lowers testosterone (also called metastatic hormone‑sensitive prostate cancer).</p><p>&nbsp;</p><p><strong>How </strong><strong>NUBEQA works</strong></p><p>NUBEQA blocks the activity of male sex hormones called androgens, such as testosterone. By blocking these hormones, darolutamide stops prostate cancer cells from growing and dividing<em>.</em></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take NUBEQA if</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are allergic to darolutamide or any of the other ingredients of this medicine (listed in section&nbsp;6)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are a woman who is or may become pregnant.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before taking NUBEQA if</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have problems with your kidneys</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have problems with your liver</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have any heart conditions including heart rhythm problems or if you are using medicines for these conditions</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you had a surgery to treat blood vessel conditions.</p><p>&nbsp;</p><p>Taking this medicine may affect your liver tests. If your blood tests show abnormal results of your liver function, your doctor may decide to stop treatment permanently.</p><p><strong><u>&nbsp;</u></strong></p><p><strong>Children and adolescents</strong></p><p>This medicine is not for use in children and adolescents under 18&nbsp;years. Prostate cancer does not occur in this age group.</p><p>&nbsp;</p><p><strong>Other medicines and NUBEQA</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p>&nbsp;</p><p>The following medicines may influence the effect of NUBEQA, or NUBEQA may influence the effect of these medicines to treat:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bacterial infections, such as <strong>rifampicin</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; epilepsy, such as <strong>carbamazepine, phenobarbital, phenytoin</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptoms of slightly low mood and mild anxiety: <strong>St. John&#39;s wort </strong>(a herbal medicine)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high cholesterol, such as <strong>rosuvastatin, fluvastatin, atorvastatin, pitavastatin</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe joint inflammation, severe cases of the skin disease psoriasis, and cancers: <strong>methotrexate</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammatory bowel diseases: <strong>sulfasalazine</strong></p><p>&nbsp;</p><p>Your doctor may therefore change the dose of the medicines that you are taking.</p><p>&nbsp;</p><p><strong>Pregnancy, breast-feeding and fertility</strong></p><p><strong>NUBEQA is not for use in women</strong>.</p><p>This medicine could possibly have an effect on male fertility.</p><p>Follow these advices during and for 1&nbsp;week after stopping:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; use a highly effective method of contraception to prevent pregnancy, if you are having sex with a woman who can become pregnant.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; use a condom to protect the unborn baby, if you are having sex with a pregnant woman.</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>This medicine is unlikely to affect your ability to drive and use machines.</p><p>&nbsp;</p><p><strong>NUBEQA contains lactose</strong></p><p>If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>&nbsp;</strong></p><p><strong>The recommended dose is</strong></p><p>2&nbsp;tablets 2&nbsp;times daily</p><p>&nbsp;</p><p>Your doctor may reduce your dose to 1&nbsp;tablet 2&nbsp;times daily, if you have problems with your liver or kidneys.</p><p>&nbsp;</p><p><strong>Method of use</strong></p><p>Swallow the tablets whole, take them with food and a glass of water.</p><p>&nbsp;</p><p>Your doctor may also prescribe other medicines while you are taking NUBEQA.</p><p>&nbsp;</p><p><strong>If you take more NUBEQA than you should</strong></p><p>Continue the treatment with the next dose as scheduled.</p><p>&nbsp;</p><p><strong>If you forget to take NUBEQA</strong></p><p>Take your missed dose as soon as you remember before the next scheduled dose. Do not take a double dose to make up for 1 or more forgotten tablets.</p><p><strong>&nbsp;</strong></p><p><strong>If you stop taking NUBEQA</strong></p><p>Do not stop taking this medicine unless your doctor tells you to.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Side effects of NUBEQA occur with the following frequencies:</p><p><strong>&nbsp;</strong></p><p><strong>In patients with non-metastatic castration-resistant prostate cancer</strong></p><p><strong>Very common side effects</strong> (may affect more than&nbsp;1 in 10&nbsp;people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tiredness</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests showing reduced number of a white blood cell type called neutrophils</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests showing increased levels of substances produced by the liver: bilirubin, aspartate transaminase</p><p>&nbsp;</p><p><strong>Common side effects </strong>(may affect up to&nbsp;1 in 10&nbsp;people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blockage of the arteries in the heart</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart failure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in arms and legs</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in muscles and bones</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; broken bones</p><p>&nbsp;</p><p><strong>In patients with metastatic </strong><strong>hormone‑sensitive</strong> <strong>prostate cancer</strong></p><p><strong>Very common side effects</strong> (may affect more than&nbsp;1 in 10&nbsp;people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests showing reduced number of a white blood cell type called neutrophils</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood tests showing increased levels of substances produced by the liver: bilirubin, alanine transaminase and aspartate transaminase</p><p>&nbsp;</p><p><strong>Common side effects </strong>(may affect up to&nbsp;1 in 10&nbsp;people):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; broken bones</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breast enlargement in men</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><thead><tr><td colspan="2" style="vertical-align:top"><p><strong>To report any side effect(s):</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p><strong>Kuwait:</strong></p><p>Drug &amp;Food Control, Ministry of Health ,Kuwait</p><p>Tel.: +965-24811532</p><p>Fax: +965-24811507</p><p>Email : Adr_reporting@moh.gov.kw</p><p>Website: http://eservices.moh.gov.kw/SPCMS/DrugCmp.aspx</p></td><td style="vertical-align:top"><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>United Arab Emirates (UAE):</strong></p><p>Pharmacovigilance &amp; Medical Device section</p><p>Tel: 80011111 / +971 42301000&nbsp;</p><p>Email: pv@mohap.gov.ae</p><p>Website: www.mohap.gov.ae</p><p>P.O.Box 1853 Dubai</p></td><td style="vertical-align:top"><p><strong>Egypt:</strong></p><p>Egyptian Pharmaceutical Vigilance Centre</p><p>Hotline: 15301</p><p>Email: pv.followup@edaegypt.gov.eg</p><p>Website: www.edaegypt.gov.eg</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Oman:</strong></p><p>Tel: +968 - 2444 1999</p><p>Fax: +968 - 24602287</p><p>Email: pharma-vigil@moh.gov.om</p><p>Website: www.moh.gov.om</p></td><td style="vertical-align:top"><p><strong>Jordan:</strong></p><p>Tel:+ 962-6-5632000</p><p>JFDA email : jpc@jfda.jo</p><p>JFDA website: www.jfda.jo</p><p>http://primaryreporting.who-umc.org/JO</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Other Countries:</strong></p><p>Please contact the relevant competent authority</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and on each blister after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Do not store above 30&deg;C.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What </strong><strong>NUBEQA contains</strong></p><p>The active substance is darolutamide. Each film‑coated tablet contains 300&nbsp;mg of darolutamide.</p><p>The other ingredients are:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; calcium hydrogen phosphate (E&nbsp;341)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; croscarmellose sodium</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hypromellose</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lactose monohydrate</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; macrogol (E&nbsp;1521)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; magnesium stearate (E&nbsp;470b)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; povidone (E&nbsp;1201)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; titanium dioxide (E&nbsp;171)</p><p>&nbsp;</p><p>See &ldquo;NUBEQA contains lactose&rdquo; in section&nbsp;2 for more information.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	What NUBEQA looks like and contents of the pack
	The film coated tablets (tablets) are white to off white, oval with a length of 16 mm and a width of 8 mm. They are marked with “300” on one side, and “BAYER” on the other side.
	
Each carton contains 112 film coated tablets consisting of 7 blisters
Each blister contains 16 film coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Bulk Manufacturer:</strong></p><p>Orion Corporation, Orion Pharma</p><p>Orionintie 1</p><p>02200 Espoo, Finland</p><p><strong>&nbsp;</strong></p><p><strong>Packaging and Batch release site:</strong></p><p>Orion Corporation, Orion Pharma</p><p>Joensuunkatu 7</p><p>24100 Salo, Finland</p><p><strong>&nbsp;</strong></p><p><strong>Marketing Authorisation Holder:</strong></p><p>Bayer AG,</p><p>51368 Leverkusen, Germany.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	This leaflet was last revised in February 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي نوبيكا على المادة الفعالة دارولوتاميد. يتم استخدامه لعلاج الرجال البالغين المصابين بسرطان البروستات الذي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; لم ينتشر إلى أجزاء أخرى من الجسم ولم يعد يستجيب للعلاج الطبي أو الجراحي الذي يخفض هرمون التستوستيرون (يُسمى أيضاً سرطان البروستات الغير نقيلي (الغير منتشر) المقاوم للاخصاء).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; انتشر إلى أجزاء أخرى من الجسم ويستجيب للعلاج الطبي أو الجراحي الذي يخفض هرمون التستوستيرون (ويسمى أيضًا سرطان البروستات الحساس للهرمون النقيلي(المنتشر))</p><p dir="RTL"><strong>كيف يعمل نوبيكا</strong></p><p dir="RTL">يمنع نوبيكا نشاط الهرمونات الجنسية الذكرية التي تسمى الأندروجينات، مثل هرمون التستوستيرون. عن طريق منع هذه الهرمونات، يوقف دارولوتاميد خلايا سرطان البروستات من النمو والانقسام.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول نوبيكا في الحالات التالية:</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; لديك حساسية من دارولوتاميد أو من أي مكونات أخرى لهذا الدواء (المذكورة في الجزء رقم 6)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; أنت امرأة حامل أو قد تصبحين حاملاً.</p><p dir="RTL"><strong>المحاذير والاحتياطات</strong></p><p dir="RTL">تحدث إلى طبيبك أو الصيدلي قبل تناول نوبيكا في الحالات التالية:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; لديك مشاكل في الكليتين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; لديك مشاكل في الكبد</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; لديك أي مشاكل في القلب بما في ذلك مشاكل في ضربات القلب أو إذا كنت تستخدم أدوية لهذه الحالات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; خضعت لعملية جراحية لعلاج مشاكل في الأوعية الدموية.</p><p dir="RTL">قد يؤثر تناول هذا الدواء على اختبارات الكبد. إذا أظهرت اختبارات الدم لديك نتائج غير طبيعية لوظائف الكبد ، فقد يقرر طبيبك إيقاف العلاج نهائيًا.</p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">هذا الدواء ليس للاستخدام في الأطفال والمراهقين أقل من سن 18 سنة. لا يحدث سرطان البروستات في هذه الفئة العمرية.</p><p dir="RTL"><strong>أدوية أخرى و نوبيكا</strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً أو قد تتناول أي أدوية أخرى.</p><p dir="RTL">قد تؤثر الأدوية التالية على تأثير نوبيكا، أو قد يؤثر نوبيكا على تأثير هذه الأدوية في العلاج:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; حالات العدوى البكتيرية، التي يستخدم فيها علاج مثل الريفامبيسين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; حالات الصرع، التي يستخدم فيها علاج مثل الكاربامازيبين، الفينوباربيتال، الفينيتوين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; حالات أعراض المزاج المنخفض قليلاً والقلق الخفيف: التي تستخدم فيها نبتة سانت جون (دواء عشبي)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; حالات ارتفاع نسبة الكوليسترول، التي يستخدم فيها علاج مثل رسيوفاستاتين، فلوفاستاتين، أتورفاستاتين، بيتافاستاتين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; حالات التهاب المفاصل الشديد، والحالات الشديدة من الصدفية والامراض الجلدية، والسرطانات: التي يستخدم فيها علاج مثل الميثوتريكسات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; حالات أمراض التهاب الأمعاء: التي يستخدم فيها علاج مثل السلفاسالازين</p><p dir="RTL">لذلك قد يغير طبيبك جرعة الأدوية التي تتناولها.</p><p dir="RTL"><strong>الحمل، الرضاعة الطبيعية والخصوبة</strong></p><p dir="RTL">لا يستخدم نوبيكا لدى النساء.</p><p dir="RTL">قد يكون لهذا الدواء تأثير على خصوبة الرجال.</p><p dir="RTL">اتبع هذه النصائح خلال ولمدة أسبوع بعد التوقف عن تناول نوبيكا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تمارس الجنس مع امرأة يمكن أن تحمل، استخدم وسيلة فعالة للغاية لمنع الحمل لعدم حدوث حمل.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تمارس الجنس مع امرأة حامل، يجب عليك استخدام الواقي الذكري (العازل الطبي) لحماية الجنين.</p><p dir="RTL"><strong>قيادة السيارة واستخدام الآلات</strong></p><p dir="RTL">من غير المحتمل أن يؤثر هذا الدواء على قدرتك على القيادة واستخدام الآلات.</p><p dir="RTL"><strong>يحتوي نوبيكا على اللاكتوز</strong></p><p dir="RTL">إذا قال لك طبيبك من قبل أنك تعاني من عدم تحمل لبعض السكريات، اتصل بطبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">دائماً تناول هذا الدواء تماماً كما أخبرك طبيبك أو الصيدلي. إذا لم تكن متأكداً، استشر طبيبك أو الصيدلي.</p><p dir="RTL"><strong>الجرعة الموصي بها هي كما يلي:</strong></p><p dir="RTL">تناول قرصين(حبتين) مرتين يومياً</p><p dir="RTL">قد يقلل طبيبك جرعتك إلى قرص واحد مرتين يومياً، إذا كانت لديك مشاكل في الكبد أو الكليتين.</p><p dir="RTL"><strong>طريقة تناول الأقراص</strong></p><p dir="RTL">تناول الأقراص مع الطعام وكوب من الماء كاملة.</p><p dir="RTL">قد يصف طبيبك أيضاً أدوية أخرى أثناء تناولك نوبيكا.</p><p dir="RTL"><strong>إذا تناولت نوبيكا أكثر مما يجب</strong></p><p dir="RTL">استمر في العلاج بالجرعة التالية كما هو مقرر.</p><p dir="RTL"><strong>إذا تم نسيان تناول نوبيكا</strong></p><p dir="RTL">تناول الجرعة المنسية بمجرد أن تتذكر قبل الجرعة التالية المقررة. لا تتناول جرعة مضاعفة لتعويض قرص واحد أو أكثر من الأقراص المنسية.</p><p dir="RTL"><strong>إذا توقفت عن تناول نوبيكا</strong></p><p dir="RTL">لا تتوقف عن تناول هذا الدواء ما لم يخبرك طبيبك بذلك.</p><p dir="RTL">إذا كان لديك أي أسئلة أخرى حول تناول هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثاراً جانبية، على الرغم من عدم إصابة الجميع بها.</p><p dir="RTL">تحدث الآثار الجانبية لنوبيكا بالتكرار الآتي:</p><p dir="RTL"><strong>لدى المرضى الذين يعانون من سرطان البروستات المقاوم للإخصاء غير النقيلي (الغير منتشر)</strong></p><p dir="RTL"><strong>آثار جانبية شائعة جداً </strong>(يمكن أن تصيب أكثر من 1 من كل 10 من المرضى):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; إعياء (تعب)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; اختبارات الدم تظهر انخفاض عدد خلايا الدم البيضاء التي تسمى العدلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; اختبارات الدم تُظهر مستويات متزايدة من المواد التي ينتجها الكبد: البيليروبين و الأسبارتات ترانساميناز</p><p dir="RTL"><strong>آثار جانبية شائعة</strong> (قد تصيب ما يصل إلى 1 من كل 10 من المرضى):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; انسداد الشرايين في القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; فشل في وظائف القلب</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ألم في الذراعين والساقين</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; آلام في العضلات والعظام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; كسر العظام</p><p dir="RTL"><strong>في المرضى الذين يعانون من سرطان البروستاتا الحساس للهرمون النقيلي (المنتشر)</strong></p><p dir="RTL"><strong>آثار جانبية شائعة جداً </strong>(يمكن أن تصيب أكثر من 1 من كل 10 من المرضى):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ضغط دم مرتفع</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; اختبارات الدم تظهر انخفاض عدد خلايا الدم البيضاء التي تسمى العدلات</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; اختبارات الدم تُظهر مستويات متزايدة من المواد التي ينتجها الكبد: البيليروبين ، والألانين ترانس أمينيز والأسبارتات ترانساميناز</p><p dir="RTL"><strong>آثار جانبية شائعة</strong> (قد تصيب ما يصل إلى 1 من كل 10 من المرضى):</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; كسر العظام</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; تضخم الثدي عند الرجال</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إذا حصل معك أي آثار جانبية، فتحدث مع طبيبك أو الصيدلي. يشمل ذلك أي آثار جانبية محتملة غير مذكورة في هذه النشرة. من خلال الإبلاغ عن الآثار الجانبية، يمكنك المساعدة في توفير المزيد من المعلومات حول سلامة تناول هذا الدواء.</p><p dir="RTL">&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><thead><tr><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>للإبلاغ عن الأعراض الجانبية:</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p dir="RTL"><strong>الكويت:</strong></p><p dir="RTL">مراقبة الأدوية والغذاء، وزارة الصحة</p><p dir="RTL">هاتف: 24811532-965+</p><p dir="RTL">فاكس: 24811507-965+</p><p dir="RTL">البريد الالكتروني: &nbsp;Adr_reporting@moh.gov.kw</p><p dir="RTL">الموقع الالكتروني:</p><p dir="RTL">http://eservices.moh.gov.kw/spcms/drugcmp.aspx</p></td><td style="vertical-align:top"><p dir="RTL"><strong>السعودية</strong><strong>:</strong></p><p dir="RTL">المركز الوطني للتيقظ الدوائي</p><p dir="RTL">مركز اتصال الهيئة العامة للغذاء والدواء: 19999</p><p dir="RTL">البريد الالكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الالكتروني: https://ade.sfda.gov.sa</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>الإمارات العربية المتحدة:</strong></p><p dir="RTL">قسم التيقظ الدوائي والأجهزة الطبية</p><p dir="RTL">هاتف: 80011111 / 42301000 &ndash; 971+</p><p dir="RTL">البريد الاكتروني: pv@mohap.gov.ae</p><p dir="RTL">الموقع الالكتروني: www.mohap.gov.ae</p><p dir="RTL">ص.ب. 1853 دبي</p></td><td style="vertical-align:top"><p dir="RTL"><strong>مصر:</strong></p><p dir="RTL">مركز اليقظة الصيدلية المصري</p><p dir="RTL">الخط الساخن: 15301</p><p dir="RTL">البريد الالكتروني: pv.followup@edaegypt.gov.eg</p><p dir="RTL">الموقع الالكتروني: www.edaegypt.gov.eg</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL"><strong>سلطنة عمان:</strong></p><p dir="RTL">هاتف: 24441999 &ndash; 968+</p><p dir="RTL">فاكس: 24602287 &ndash; 968+</p><p dir="RTL">البريد الالكتروني: pharma-vigil@moh.gov.om</p><p dir="RTL">الموقع الالكتروني: &nbsp;www.moh.gov.om</p></td><td style="vertical-align:top"><p dir="RTL"><strong>الأردن:</strong></p><p dir="RTL">هاتف: 5632000-6-962+</p><p dir="RTL">البريد الالكتروني: jpc@jfda.jo</p><p dir="RTL">الموقع الالكتروني: www.jfda.jo</p><p dir="RTL">http://primaryreporting.who-umc.org/JO</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p dir="RTL"><strong>بلدان أخرى:</strong></p><p dir="RTL">يرجى الاتصال بالسلطة المختصة ذات الصلة.</p></td></tr></tbody></table>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيداً عن أنظار ومتناول الأطفال.</p><p dir="RTL">لا تتناول هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العلبة الكرتون للعبوة وعلى كل شريط بعد كلمة EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">يحفظ في درجة حرارة لا تزيد عن 30 درجة مئوية.</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو عن طريق النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يحتوي نوبيكا</strong></p><p dir="RTL">المادة الفعالة هي دارولوتاميد</p><p dir="RTL">يحتوي كل قرص مغلف على 300 مجم دارولوتاميد.</p><p dir="RTL">المواد الاخرى هي كما يلي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; فوسفات هيدروجين الكالسيوم (E 341)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; كروسكارميلوز الصوديوم</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; هايبروميلوز</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; مونوهيدرات اللاكتوز</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ماكروجول (E 1521)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ستيرات المغنيسيوم (E 470b)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; بوفيدون (E 1201)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp; ثاني أكسيد التيتانيوم (E 171)</p><p dir="RTL">انظر &laquo;نوبيكا يحتوي على اللاكتوز&raquo; في الجزء رقم 2 لمزيد من المعلومات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>كيف يبدو نوبيكا ومحتويات العبوة</strong></p><p dir="RTL">الأقراص المغلفة (الأقراص) بيضاء تميل إلى البياض، بيضاوية الشكل بطول 16 ملم وعرض 8 ملم. تم وضع علامة &laquo;300&raquo; على جانب واحد، و &laquo;BAYER&raquo; على الجانب الآخر.</p><p dir="RTL">تحتوي كل علبة كارتون على 112 قرص مغلف&nbsp; معبئة في 7 شرائط.</p><p dir="RTL">كل شريط يحتوي على 16 قرص مغلف.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مصنع البلك</strong></p><p dir="RTL">شركة أوريون، أوريون فارما</p><p dir="RTL">أوريونينتي 1</p><p dir="RTL">02200 أسبو، فنلندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التعبئة و الإفراج</strong></p><p dir="RTL">شركة أوريون، أوريون فارما</p><p dir="RTL">جونسووناتو 7</p><p dir="RTL">24100 سالو، فنلندا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>صاحب ترخيص التسويق</strong></p><p dir="RTL">باير ايه جي</p><p dir="RTL">51368 ليفركوزن</p><p dir="RTL">ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تم مراجعة هذه النشرة أخر مرة في فبراير 2023.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                NUBEQA 300 mg film coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film coated tablet contains 300 mg of darolutamide.

Excipient with known effect

Each film coated tablet contains 186 mg of lactose monohydrate (see section 4.4).

For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film coated tablet (tablet).

White to off white, oval tablets with a length of 16 mm and a width of 8 mm, marked with “300” on one side, and “BAYER” on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NUBEQA is indicated for the treatment of adult men with</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non‑metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section&nbsp;5.1).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; metastatic hormone‑sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section&nbsp;5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment should be initiated and supervised by a specialist physician experienced in treatment of prostate cancer.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose is 600&nbsp;mg darolutamide (two tablets of 300&nbsp;mg) taken twice daily, equivalent to a total daily dose of 1200&nbsp;mg (see section&nbsp;5.2).</p><p>&nbsp;</p><p>Darolutamide should be continued until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p>Medical castration with a luteinising hormone‑releasing hormone (LHRH) analogue should be continued during treatment of patients not surgically castrated.</p><p>&nbsp;</p><p><em><u>metastatic hormone‑sensitive prostate cancer (mHSPC)</u></em></p><p>mHSPC patients should start darolutamide in combination with docetaxel (see section&nbsp;5.1). The first of 6&nbsp;cycles of docetaxel should be administered within 6&nbsp;weeks after the start of darolutamide treatment. The recommendation in the product information of docetaxel should be followed. Treatment with darolutamide should be continued until disease progression or unaccepatble toxicity even if a cycle of docetaxel is delayed, interrupted, or discontinued.</p><p>&nbsp;</p><p><em>Missed dose</em></p><p>If a dose is missed, the dose should be taken as soon as the patient remembers prior to the next scheduled dose. The patient should not take two doses together to make up for a missed dose.</p><p>&nbsp;</p><p><em>Dose modification</em></p><p>If a patient experiences a &ge;&nbsp;Grade&nbsp;3 toxicity or an intolerable adverse reaction related to darolutamide (see section&nbsp;4.8), dosing should be withheld or reduced to 300&nbsp;mg twice daily until symptoms improve. Treatment may then be resumed at a dose of 600&nbsp;mg twice daily.</p><p>&nbsp;</p><p>Dose reduction below 300&nbsp;mg twice daily is not recommended, because efficacy has not been established.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>No dose adjustment is necessary in elderly patients (see section&nbsp;5.2).</p><p><em>&nbsp;</em></p><p><em>Renal impairment</em></p><p>No dose adjustment is necessary for patients with mild or moderate renal impairment.</p><p>For patients with severe renal impairment (eGFR 15‑29&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) not receiving haemodialysis, the recommended starting dose is 300&nbsp;mg twice daily (see sections&nbsp;4.4 and 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is necessary for patients with mild hepatic impairment.</p><p>The available data on darolutamide pharmacokinetics in moderate hepatic impairment is limited. Darolutamide has not been studied in patients with severe hepatic impairment.</p><p>For patients with moderate and severe hepatic impairment (Child‑Pugh Classes&nbsp;B and C), the recommended starting dose is 300&nbsp;mg twice daily (see sections&nbsp;4.4 and 5.2.).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>There is no relevant use of darolutamide in the paediatric population.</p><p><u>&nbsp;</u></p><p><u>Method of administration</u></p><p>&nbsp;</p><p>NUBEQA is for oral use.</p><p>&nbsp;</p><p>The tablets should be taken whole with food (see section&nbsp;5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Women who are or may become pregnant (see section 4.6).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Renal impairment</u></p><p><u>&nbsp;</u></p><p>The available data in patients with severe renal impairment are limited.</p><p>As exposure might be increased those patients should be closely monitored for adverse reactions (see sections&nbsp;4.2 and 5.2).</p><p>&nbsp;</p><p><u>Hepatic impairment</u></p><p><u>&nbsp;</u></p><p>The available data in patients with moderate hepatic impairment are limited, and darolutamide has not been studied in patients with severe hepatic impairment.</p><p>As exposure might be increased those patients should be closely monitored for adverse reactions (see sections&nbsp;4.2 and 5.2).</p><p>&nbsp;</p><p><u>Recent cardiovascular disease</u></p><p><u>&nbsp;</u></p><p>Patients with clinically significant cardiovascular disease in the past 6&nbsp;months including stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, and symptomatic congestive heart failure were excluded from the clinical studies. Therefore, the safety of darolutamide in these patients has not been established.</p><p>If NUBEQA is prescribed, patients with clinically significant cardiovascular disease should be treated for these conditions according to established guidelines.</p><p><u>&nbsp;</u></p><p><u>Hepatic transaminase elevations</u></p><p>&nbsp;</p><p>In case of hepatic transaminase elevations suggestive of idiosyncratic drug‑induced liver injury related to darolutamide, permanently discontinue treatment with darolutamide (see section&nbsp;4.8).</p><p><u>&nbsp;</u></p><p><u>Concomitant use with other medicinal products</u></p><p><u>&nbsp;</u></p><p>Use of strong CYP3A4 and P‑gp inducers during treatment with darolutamide may decrease the plasma concentration of darolutamide and is not recommended, unless there is no therapeutic alternative. Selection of an alternate concomitant medicinal product with less potential to induce CYP3A4 or P‑gp should be considered (see section 4.5).</p><p><u>&nbsp;</u></p><p>Patients should be monitored for adverse reactions of BCRP, OATP1B1 and OATP1B3 substrates as co‑administration with darolutamide may increase the plasma concentrations of these substrates.</p><p>Co‑administration with rosuvastatin should be avoided unless there is no therapeutic alternative (see section&nbsp;4.5).</p><p>&nbsp;</p><p><u>Androgen deprivation therapy may prolong the QT interval</u></p><p><u>&nbsp;</u></p><p>In patients with a history of risk factors for QT prolongation and in patients receiving concomitant medicinal products that might prolong the QT interval (see section&nbsp;4.5), physicians should assess the benefit‑risk ratio including the potential for Torsade de pointes prior to initiating NUBEQA.</p><p><u>&nbsp;</u></p><p><u>Information about excipients</u></p><p><u>&nbsp;</u></p><p>NUBEQA contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose‑galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Effects of other medicinal products on darolutamide</u></p><p>&nbsp;</p><p><em>CYP3A4 and P‑gp inducers</em></p><p>Darolutamide is a substrate of CYP3A4 and P‑glycoprotein (P‑gp).</p><p>Use of strong and moderate CYP3A4 inducers and P‑gp inducers (e.g. carbamazepine, phenobarbital, St. John&#39;s Wort, phenytoin, and rifampicin) during treatment with darolutamide is not recommended, unless there is no therapeutic alternative. Selection of an alternate concomitant medicinal product, with no or weak potential to induce CYP3A4 or P‑gp should be considered.</p><p>Repeated administration of rifampicin (600&nbsp;mg), a strong CYP3A4 and a P‑gp inducer, with a single dose of darolutamide (600&nbsp;mg) together with food, resulted in a decrease of 72% in mean exposure (AUC<sub>0‑72</sub>) and a decrease of 52% in C<sub>max</sub> of darolutamide.</p><p>&nbsp;</p><p><em>CYP3A4, P‑gp and BCRP inhibitors</em></p><p>Darolutamide is a substrate of CYP3A4, P‑gp and breast cancer resistance protein (BCRP).</p><p>No clinically relevant drug‑drug interaction is expected in case of CYP3A4, P‑gp or BCRP inhibitor administration. Darolutamide may be given concomitantly with CYP3A4, P‑gp or BCRP inhibitors. Concomitant use of darolutamide with a combined P‑gp and strong CYP3A4 inhibitor increases darolutamide exposure which may increase the risk of darolutamide adverse reactions. It is recommended to monitor patients more frequently for darolutamide adverse reactions and modify darolutamide dose as needed.</p><p>Administration of itraconazole (200&nbsp;mg twice daily on day&nbsp;1 and once daily on the following 7&nbsp;days), a strong CYP3A4, P‑gp and BCRP inhibitor, with a single dose of darolutamide (600&nbsp;mg on day&nbsp;5 together with food) resulted in a 1.7‑fold increase in mean exposure (AUC<sub>0‑72</sub>) and a 1.4‑fold increase of C<sub>max</sub> of darolutamide.</p><p>&nbsp;</p><p><em>UGT1A9 inhibitors</em></p><p>Darolutamide is a substrate of UGT1A9.</p><p>No clinically relevant drug‑drug interaction is expected in case of UGT1A9 inhibitor administration.</p><p>Darolutamide may be given concomitantly with UGT1A9 inhibitors.</p><p>A population pharmacokinetic analysis showed that co-administration of UGT1A9 inhibitors with darolutamide resulted in a 1.2‑fold increase in exposure (AUC<sub>0-72</sub>) of darolutamide.</p><p>&nbsp;</p><p><em>Docetaxel</em></p><p>Administration of darolutamide in combination with docetaxel resulted in no clinically relevant changes in the pharmacokinetics of darolutamide in mHSPC patients (see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Effects of darolutamide on other medicinal products</u></p><p>&nbsp;</p><p><em>BCRP, OATP1B1 and OATP1B3 substrates</em></p><p>Darolutamide is an inhibitor of breast cancer resistance protein (BCRP) and Organic Anion Transporting Polypeptides (OATP) 1B1 and 1B3.</p><p>Co‑administration of rosuvastatin should be avoided unless there is no therapeutic alternative. Selection of an alternative concomitant medicinal product with less potential to inhibit BCRP, OATP1B1 and OATP1B3 should be considered.</p><p>Administration of darolutamide (600&nbsp;mg twice daily for 5&nbsp;days) prior to co‑administration of a single dose of rosuvastatin (5&nbsp;mg) together with food resulted in approximately 5‑fold increase in mean exposure (AUC) and C<sub>max</sub> of rosuvastatin.</p><p>Co‑administration of darolutamide with other BCRP substrates should be avoided where possible.</p><p>Co‑administration of darolutamide may increase the plasma concentrations of other concomitant BCRP, OATP1B1 and OATP1B3 substrates (e.g. methotrexate, sulfasalazine, fluvastatin, atorvastatin, pitavastatin). Therefore, it is recommended to monitor patients for adverse reactions of BCRP, OATP1B1 and OATP1B3 substrates. In addition, the related recommendation in the product information of these substrates should be followed when co‑administered with darolutamide.</p><p>&nbsp;</p><p><em>P‑gp substrates</em></p><p>No clinically relevant drug‑drug interaction is expected in case of P‑gp substrate administration. Darolutamide may be given concomitantly with P‑gp substrates (e.g. digoxin, verapamil or nifedipine). Co‑administration of darolutamide together with the sensitive P‑gp substrate dabigatran etexilate did not reveal any increase in exposure (AUC and C<sub>max</sub>) of dabigatran.</p><p>&nbsp;</p><p><em>CYP3A4 substrates</em></p><p>Darolutamide is a mild inducer of CYP3A4.</p><p>No clinically relevant drug‑drug interaction is expected in case of CYP substrate administration. Darolutamide may be given concomitantly with CYP substrates (e.g. warfarin, L‑thyroxine, omeprazole).</p><p>Administration of darolutamide (600&nbsp;mg twice daily for 9&nbsp;days) prior to co‑administration of a single dose of the sensitive CYP3A4 substrate midazolam (1&nbsp;mg) together with food, decreased the mean exposure (AUC) and C<sub>max</sub> of midazolam by 29% and 32%, respectively.</p><p>Darolutamide did not inhibit the metabolism of selected CYP substrates <em>in vitro </em>at clinically relevant concentrations.</p><p>&nbsp;</p><p><em>Docetaxel</em></p><p>Administration of darolutamide in combination with docetaxel resulted in no clinically relevant changes in the pharmacokinetics of docetaxel in mHSPC patients (see section&nbsp;5.1).</p><p>&nbsp;</p><p><u>Medicinal products that prolong the QT interval</u></p><p><u>&nbsp;</u></p><p>Since androgen deprivation treatment may prolong the QT interval, the co‑administration with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes should be carefully evaluated. These include medicinal products such as class&nbsp;IA (e.g., quinidine, disopyramide) or class&nbsp;III (e.g., amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, and antipsychotics (e.g. haloperidol).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product is not indicated in women of childbearing potential. It is not to be used in women who are, or may be, pregnant or breast‑feeding (see sections&nbsp;4.1 and 4.3).</p><p><u>&nbsp;</u></p><p><u>Women of childbearing potential / contraception in males and females</u></p><p>&nbsp;</p><p>It is not known whether darolutamide or its metabolites are present in semen. If the patient is engaged in sexual activity with a woman of childbearing potential, a highly effective contraceptive method (&lt;&nbsp;1% failure rate per year) should be used during and for 1&nbsp;week after completion of treatment with NUBEQA to prevent pregnancy.</p><p><u>&nbsp;</u></p><p><u>Pregnancy </u></p><p>&nbsp;</p><p>Based on its mechanism of action, darolutamide may cause foetal harm. No non‑clinical reproductive toxicity studies have been conducted (see section&nbsp;5.3).</p><p>It is not known whether darolutamide or its metabolites are present in semen. If the patient is engaged in sexual activity with a pregnant woman, a condom should be used during and for 1&nbsp;week after completion of treatment with NUBEQA. Exposure of the foetus to an androgen receptor inhibitor through seminal transfer to the pregnant woman has to be avoided, as this could affect development of the foetus.</p><p>&nbsp;</p><p><u>Breast‑feeding</u></p><p>&nbsp;</p><p>It is unknown whether darolutamide or its metabolites are excreted in human milk. No studies in animals have been conducted to evaluate the excretion of darolutamide or its metabolites into milk (see section&nbsp;5.3). A risk to the breast‑fed child cannot be excluded.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>There are no human data on the effect of darolutamide on fertility.</p><p>Based on animal studies, NUBEQA may impair fertility in males of reproductive potential (see section&nbsp;5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NUBEQA has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most frequently observed adverse reactions in patients with</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nmCRPC receiving darolutamide are fatigue/asthenic conditions (15.8%)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mHSPC receiving darolutamide in combination with docetaxel are rash (16.6%) and hypertension (13.8%).</p><p>&nbsp;</p><p>For additional safety information when darolutamide is administered in combination, refer to the product information of the individual medicinal products.</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>&nbsp;</p><p>The adverse reactions observed in patients with nmCRPC treated with darolutamide are listed in Table&nbsp;1. The adverse reactions observed in patients with mHSPC treated with darolutamide in combination with docetaxel are listed in Table&nbsp;2.</p><p>Adverse reactions are classified according to System Organ Class. They are grouped according to their frequencies. Frequency groups are defined by the following convention: very common (&ge;&nbsp;1/10); common (&ge;&nbsp;1/100 to &lt;&nbsp;1/10); uncommon (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100); rare (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000); very rare (&lt;&nbsp;1/10,000); not known (cannot be estimated from the available data).</p><p>Within each frequency group, adverse reactions are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p><strong>Table&nbsp;1: Adverse reactions reported in the ARAMIS study<sup>a</sup></strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><thead><tr><td style="vertical-align:top"><p><strong>System organ class<br />(MedDRA)</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ischaemic heart disease<sup>b</sup></p><p>Heart failure<sup>c</sup></p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash<sup>d</sup></p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pain in extremity</p><p>Musculoskeletal pain</p><p>Fractures</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Fatigue/asthenic conditions<sup>e</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations<sup>f</sup></p></td><td style="vertical-align:top"><p>Neutrophil count decreased</p><p>Blood bilirubin increased</p><p>AST increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>The median duration of exposure was 14.8&nbsp;months (range: 0.0&nbsp;to&nbsp;44.3&nbsp;months) in patients treated with darolutamide and 11.0&nbsp;months (range: 0.1&nbsp;to&nbsp;40.5&nbsp;months) in patients treated with placebo.</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Includes arteriosclerosis coronary artery, coronary artery disease, coronary artery occlusion, coronary artery stenosis, acute coronary syndrome, acute myocardial infarction, angina pectoris, angina unstable, myocardial infarction, myocardial ischaemia.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes cardiac failure, cardiac failure acute, cardiac failure chronic, cardiac failure congestive, cardiogenic shock.</p><p><sup>d&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Includes rash, rash macular, rash maculo‑papular, rash papular, rash pustular, erythema, dermatitis.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes fatigue and asthenia, lethargy and malaise.</p><p><sup>f&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. The incidence is based on values reported as laboratory abnormalities.</p><p>&nbsp;</p><p><strong>Table&nbsp;2: Adverse reactions reported in mHSPC patients treated with darolutamide in combination with docetaxel in the ARASENS study</strong><sup>a, b</sup></p><table border="1" cellspacing="0" cellpadding="0" style="width:99%"><thead><tr><td style="vertical-align:top"><p><strong>System organ class<br />(MedDRA)</strong></p></td><td style="vertical-align:top"><p><strong>Very common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Hypertension<sup>c</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash<sup>d, e</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fractures</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Gynaecomastia</p></td></tr><tr><td style="vertical-align:top"><p>Investigations<sup>f</sup></p></td><td style="vertical-align:top"><p>Neutrophil count decreased</p><p>Blood bilirubin increased</p><p>ALT increased</p><p>AST increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The median duration of exposure was 41.0&nbsp;months (range: 0.1&nbsp;to&nbsp;56.5&nbsp;months) in patients treated with darolutamide+docetaxel and 16.7&nbsp;months (range: 0.3&nbsp;to&nbsp;55.8&nbsp;months) in patients treated with placebo+docetaxel.</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions incidences may not be attributable to darolutamide alone but may contain contributions from other medicinal products used in combination.</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes hypertension, blood pressure increased, hypertensive emergency.</p><p><sup>d</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes rash, drug eruption, rash erythematous, rash follicular, rash macular, rash maculo‑papular, rash papular, rash pruritic, rash pustular, rash vesicular, erythema, dermatitis.</p><p><sup>e</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The incidence was highest during the first 6&nbsp;months of treatment.</p><p><sup>f&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. The incidence is based on values reported as laboratory abnormalities.</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p>&nbsp;</p><p><em>Hepatic transaminase elevations</em></p><p>Cases of idiosyncratic drug‑induced liver injury with grade&nbsp;3 and&nbsp;4 increases in alanine aminotransferase (ALT) and aspartate aminotransferase (AST) to &ge;&nbsp;5 and &ge;&nbsp;20&nbsp;x upper limit of normal (ULN) have been reported in darolutamide clinical studies including 1&nbsp;case of increased transaminases along with a simultaneous increase in total bilirubin to 3&nbsp;x&nbsp;ULN. Time to onset ranged from 1&nbsp;month to&nbsp;10.5&nbsp;months after initiation of darolutamide. The ALT and AST elevations were reversible upon darolutamide discontinuation. For specific recommendations, see section&nbsp;4.4.</p><p>&nbsp;</p><p><em><u>non‑metastatic castration resistant prostate cancer (nmCRPC)</u></em></p><p><em>Fatigue</em></p><p>Fatigue/asthenic conditions were reported in 15.8% of patients treated with darolutamide and in 11.4% of patients treated with placebo. Events with worst grade of 3 were reported in 0.6% of patients treated with darolutamide and in 1.1% of patients treated with placebo. Fatigue (not including asthenia, lethargy or malaise) occurred in the majority of patients (12.1% of patients treated with darolutamide and 8.7% of patients treated with placebo).</p><p>&nbsp;</p><p><em>Fractures</em></p><p>Fractures occurred in 4.2% of patients treated with darolutamide and in 3.6% of patients treated with placebo.</p><p>&nbsp;</p><p><em>Ischaemic heart disease and heart failure</em></p><p>Ischaemic heart disease occurred in 3.2% of patients treated with darolutamide and in 2.5% of patients treated with placebo. Grade&nbsp;5 events occurred in 0.3% of patients treated with darolutamide and 0.2% of patients treated with placebo. Heart failure occurred in 1.9% of patients treated with darolutamide and in 0.9% of patients treated with placebo.</p><p>&nbsp;</p><p><em>Neutrophil count decreased</em></p><p>Neutrophil count decreased was reported as a laboratory abnormality in 19.6% of patients treated with darolutamide and in 9.4% of patients treated with placebo. The median time to nadir was 256&nbsp;days. The laboratory tests abnormalities manifested predominantly as grade&nbsp;1 or&nbsp;2 intensity. Neutrophil count decreased of grade&nbsp;3 and&nbsp;4 was reported in 3.5% and 0.5% of patients, respectively. Only one patient permanently discontinued darolutamide due to neutropenia. Neutropenia was either transient or reversible (88% of patients) and were not associated with any clinically relevant signs or symptoms.</p><p>&nbsp;</p><p><em>Blood bilirubin increased</em></p><p>Bilirubin increased was reported as a laboratory abnormality in 16.4% of patients treated with darolutamide and in 6.9% of patients treated with placebo. The episodes were predominantly of grade&nbsp;1 or&nbsp;2 intensity, not associated with any clinically relevant signs or symptoms, and reversible after darolutamide was discontinued. Bilirubin increased of grade&nbsp;3 was reported in 0.1% of patients treated with darolutamide and in 0% of patients treated with placebo. In the darolutamide arm, the mean time to first onset of increased bilirubin was 153&nbsp;days, and the mean duration of the first episode was 182&nbsp;days. No patients were discontinued from treatment due to increase in bilirubin.</p><p>&nbsp;</p><p><em>AST increased</em></p><p>AST increased was reported as a laboratory abnormality in 22.5% of patients treated with darolutamide and in 13.6% of patients treated with placebo. The episodes were predominantly of grade&nbsp;1 or&nbsp;2 intensity, not associated with any clinically relevant signs or symptoms, and reversible after darolutamide was discontinued. AST increased of grade&nbsp;3 was reported in 0.5% of patients treated with darolutamide and in 0.2% of patients treated with placebo. In the darolutamide arm, the mean time to first onset of increased AST was 258&nbsp;days, and the mean duration of the first episode was 118&nbsp;days. No patients were discontinued from treatment due to increase in AST.</p><p>&nbsp;</p><p><em><u>metastatic hormone‑sensitive prostate cancer (mHSPC)</u></em></p><p><em>Hypertension</em></p><p>In the ARASENS study hypertension was reported in 13.8% of patients treated with darolutamide+docetaxel and 9.4% of patients treated with placebo+docetaxel.</p><p>Grade&nbsp;3 hypertension was reported in 6.4% of patients treated with darolutamide+docetaxel compared to 3.5% of patients treated with placebo+docetaxel. One patient had grade&nbsp;4 hypertension in each treatment arm.</p><p>One case was reported as grade&nbsp;5 hypertension with grade&nbsp;5 arteriosclerosis in the darolutamide+docetaxel arm. This patient had a long‑standing history of hypertension and smoking and the case occurred more than 3&nbsp;years after starting darolutamide treatment. Events of hypertension were reported more commonly in patients with no medical history of hypertension in both treatment arms.</p><p>&nbsp;</p><p><em>Fractures</em></p><p>Fractures occurred in 7.5% of patients treated with darolutamide+docetaxel and in 5.1% of patients treated with placebo+docetaxel.</p><p>&nbsp;</p><p><em>Neutrophil count decreased</em></p><p>Neutrophil count decreased was reported as a laboratory abnormality in 50.6% of patients treated with darolutamide+docetaxel and in 45.5% of patients treated with placebo+docetaxel. Grade&nbsp;3 and&nbsp;4 neutrophil count decreased was reported in 34.4% of patients treated with darolutamide+docetaxel and in 31.4% of patients treated with placebo+docetaxel. In both treatment arms, the incidences of neutrophil count decreased and neutropenia were highest during the first months of treatment, after which the incidence and severity of the events decreased.</p><p>&nbsp;</p><p><em>Blood bilirubin increased</em></p><p>Bilirubin increased was reported as a laboratory abnormality in 19.6% of patients treated with darolutamide+docetaxel and in 10.0% of patients treated with placebo+docetaxel. The events were predominantly of grade&nbsp;1 or&nbsp;2 intensity. Grade&nbsp;3 and&nbsp;4 bilirubin increased was reported in 0.5% of patients treated with darolutamide+docetaxel and in 0.3% of patients treated with placebo+docetaxel.</p><p>&nbsp;</p><p><em>ALT and AST increased</em></p><p>Alanine aminotransferase (ALT) increased was reported as a laboratory abnormality in 42.3% of patients treated with darolutamide+docetaxel and in 38.0% of patients treated with placebo+docetaxel. Aspartate aminotransferase (AST) increased was reported as a laboratory abnormality in 43.9% of patients treated with darolutamide+docetaxel and in 39.3% of patients treated with placebo+docetaxel. ALT and AST elevations were predominantly of grade&nbsp;1 intensity. Grade&nbsp;3 and&nbsp;4 ALT increased was reported in 3.7% of patients treated with darolutamide+docetaxel and in 3.0% of patients treated with placebo+docetaxel. Grade&nbsp;3 and&nbsp;4 AST increased was reported in 3.6% of patients treated with darolutamide+docetaxel and in 2.3% of patients treated with placebo+docetaxel.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0" style="width:605px"><tbody><tr><td style="vertical-align:top"><p><strong>Kuwait:</strong></p><p>Drug &amp;Food Control, Ministry of Health ,Kuwait</p><p>Tel.: +965-24811532</p><p>Fax: +965-24811507</p><p>Email : Adr_reporting@moh.gov.kw</p><p>Website: http://eservices.moh.gov.kw/SPCMS/DrugCmp.aspx</p></td><td style="vertical-align:top"><p><strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC).</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>United Arab Emirates (UAE):</strong></p><p>Pharmacovigilance &amp; Medical Device section</p><p>Tel: 80011111 / +971 42301000&nbsp;</p><p>Email: pv@mohap.gov.ae</p><p>Website: www.mohap.gov.ae</p><p>P.O.Box 1853 Dubai</p></td><td style="vertical-align:top"><p><strong>Egypt:</strong></p><p>Egyptian Pharmaceutical Vigilance Centre</p><p>Hotline: 15301</p><p>Email: pv.followup@edaegypt.gov.eg</p><p>Website: www.edaegypt.gov.eg</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Oman:</strong></p><p>Tel: +968 - 2444 1999</p><p>Fax: +968 - 24602287</p><p>Email: pharma-vigil@moh.gov.om</p><p>Website: www.moh.gov.om</p></td><td style="vertical-align:top"><p><strong>Jordan:</strong></p><p>Tel:+ 962-6-5632000</p><p>JFDA email : jpc@jfda.jo</p><p>JFDA website: www.jfda.jo</p><p>http://primaryreporting.who-umc.org/JO</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Other Countries:</strong></p><p>Please contact the relevant competent authority</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The highest dose of darolutamide studied clinically was 900&nbsp;mg twice daily, equivalent to a total daily dose of 1800&nbsp;mg. No dose limiting toxicities were observed with this dose.</p><p>Considering the saturable absorption (see section&nbsp;5.2) and the absence of evidence for acute toxicity, an intake of a higher than recommended dose of darolutamide is not expected to lead to toxicity.</p><p>In the event of intake of a higher than recommended dose, treatment with darolutamide can be continued with the next dose as scheduled.</p><p>There is no specific antidote for darolutamide and symptoms of overdose are not established.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Endocrine therapy, anti‑androgens; ATC code: L02BB06</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Darolutamide is an androgen receptor (AR) inhibitor with a flexible polar‑substituted pyrazole structure that binds with high affinity directly to the receptor ligand binding domain.</p><p>Darolutamide competitively inhibits androgen binding, AR nuclear translocation, and AR mediated transcription. A major metabolite, keto‑darolutamide, exhibited similar <em>in vitro</em> activity to darolutamide. Darolutamide treatment decreases prostate tumour cell proliferation leading to potent antitumour activity.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>&nbsp;</p><p>No prolongation of the mean QTcF interval (i.e., greater than 10&nbsp;ms) was observed after oral administration of 600&nbsp;mg darolutamide twice daily compared to placebo.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>Efficacy and safety were established in two randomised placebo‑controlled multicentre phase&nbsp;III studies in patients with nmCRPC (ARAMIS) and mHSPC (ARASENS). All patients received a luteinising hormone‑releasing hormone (LHRH) analogue concurrently or had a bilateral orchiectomy.</p><p>&nbsp;</p><p><em>non‑metastatic castration resistant prostate cancer (nmCRPC)</em></p><p>The efficacy and safety of darolutamide was assessed in a randomised, double‑blind, placebo‑controlled multicentre phase&nbsp;III&nbsp;study (ARAMIS) in patients with non‑metastatic (as assessed by conventional imaging CT, bone scan, MRI) castration resistant prostate cancer with a prostate‑specific antigen doubling time (PSADT) of &le;&nbsp;10&nbsp;months.</p><p>Patients were included in the trial if they had 3&nbsp;rising prostate‑specific antigen (PSA) levels after the nadir taken at least 1&nbsp;week apart during androgen deprivation therapy, PSA &ge;&nbsp;2&nbsp;ng/mL at screening and castrate level of serum testosterone &lt;&nbsp;1.7&nbsp;nmol/L.</p><p>Patients with a medical history of seizure were allowed to enter the study. There were 12&nbsp;patients (0.21%) enrolled on the darolutamide arm with a history of seizure.</p><p>Patients with uncontrolled hypertension or recent (in the past 6&nbsp;months) stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, congestive heart failure New York Heart Association (NYHA) Class&nbsp;III or&nbsp;IV were excluded from the study.</p><p>Patients with prior treatment with second generation AR inhibitors such as enzalutamide, apalutamide and darolutamide, or CYP17 enzyme inhibitors such as abiraterone acetate as well as patients receiving systemic corticosteroid with dose greater than the equivalent 10&nbsp;mg of prednisone/day within 28&nbsp;days before randomisation were excluded from the study.</p><p>In total, 1509&nbsp;patients were randomized 2:1 to receive either 600&nbsp;mg darolutamide orally twice daily (n=955) or matching placebo (n=554).</p><p>Patients with presence of pelvic lymph nodes &lt;&nbsp;2&nbsp;cm in short axis below the aortic bifurcation were allowed to enter the study. Absence or presence of metastasis was assessed by independent central radiological review. Included in these analyses were 89&nbsp;patients that were retrospectively identified with metastasis at baseline. Randomization was stratified by PSADT (&le;&nbsp;6&nbsp;months or &gt;&nbsp;6&nbsp;months) and use of osteoclast‑targeted therapy at study entry (yes or no).</p><p>&nbsp;</p><p>The following patient demographics and disease characteristics were balanced between treatment arms. The median age was 74&nbsp;years (range 48‑95) and 9% of patients were 85&nbsp;years of age or older. The racial distribution was 79% White, 13% Asian, and 3% Black. A majority of patients had a Gleason score of&nbsp;7 or higher at diagnosis (73%). The median PSADT was 4.5&nbsp;months. Nine percent (9%) of patients had prior orchiectomy, 25% of patients had prior prostatectomy and 50% of patients had at least one prior radiotherapy. Seventy‑six percent (76%) of patients received more than one prior anti‑hormonal treatment. Patients had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of&nbsp;0 (69%) or&nbsp;1 (31%) at study entry.</p><p>&nbsp;</p><p>Treatment with darolutamide continued until radiographic disease progression as assessed by conventional imaging (CT, bone scan, MRI) by blinded central review, unacceptable toxicity or withdrawal.</p><p>The primary efficacy endpoint was metastasis free survival (MFS). Secondary endpoints were overall survival (OS), time to pain progression, time to initiation of first cytotoxic chemotherapy for prostate cancer, and time to first symptomatic skeletal events (defined as occurrence of any of the following: external beam radiotherapy to relieve skeletal symptoms, new symptomatic pathologic bone fracture, spinal cord compression, or tumour‑related orthopaedic surgical intervention).</p><p>&nbsp;</p><p>Treatment with darolutamide resulted in an improvement in MFS compared to placebo (see Table&nbsp;3 and Figure&nbsp;1).</p><p>MFS results were consistent across patient subgroups regardless of PSADT, prior use of bone‑targeting agents or loco‑regional disease. Additional subgroups with consistent MFS results included PSA at baseline, Gleason score at diagnosis, age, geographical region, ECOG PS at baseline, race, and number of prior hormonal therapies.</p><p>After the primary analysis of MFS, once the study was unblinded, patients receiving placebo were offered treatment with open‑label darolutamide (cross‑over option). Among the 554&nbsp;patients randomised to placebo, 170 (31%) crossed over to receive darolutamide treatment. The OS analysis was not adjusted for confounding effects of cross‑over.</p><p>&nbsp;</p><p>At the time of the final analysis, treatment with darolutamide resulted in a statistically significant improvement in overall survival compared to placebo (median was not reached in either arm, see Table&nbsp;3 and Figure&nbsp;2).</p><p>Treatment with darolutamide also resulted in statistically significant delays in time to pain progression, time to initiation of first cytotoxic chemotherapy and time to first symptomatic skeletal event compared to placebo (see Table&nbsp;3).</p><p>&nbsp;</p><p>At the time of final analysis, the median duration of treatment in patients treated with darolutamide was 33.3&nbsp;months (range: 0.0&nbsp;to&nbsp;74.0&nbsp;months) during combined double‑blind and open‑label period.</p><p>&nbsp;</p><p>All analyses were performed in the full analysis set.</p><p>&nbsp;</p><p><strong>Table&nbsp;3: Efficacy results from the ARAMIS study</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:592px"><tbody><tr><td rowspan="2"><p><strong>Efficacy parameter</strong></p></td><td colspan="2"><p><strong>Number (%) of patients with events</strong></p></td><td colspan="2"><p><strong>Median (months) (95%&nbsp;CI)</strong></p></td><td rowspan="2"><p><strong>Hazard Ratio</strong><sup>b </sup></p><p><strong>(95%&nbsp;Confidence Interval [CI])</strong></p><p><strong>p‑value</strong></p><p><strong>(two‑sided)</strong></p></td></tr><tr><td><p><strong>Darolutamide</strong></p><p><strong>(N=955)</strong></p></td><td><p><strong>Placebo</strong><sup>a</sup></p><p><strong>(N=554)</strong></p></td><td><p><strong>Darolutamide</strong></p><p><strong>(N=955)</strong></p></td><td><p><strong>Placebo</strong><sup>a</sup></p><p><strong>(N=554)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Metastasis free survival<sup>c</sup></p></td><td style="vertical-align:top"><p>221 (23.1%)</p></td><td style="vertical-align:top"><p>216 (39.0%)</p></td><td style="vertical-align:top"><p>40.4</p><p>(34.3, NR)</p></td><td style="vertical-align:top"><p>18.4</p><p>(15.5, 22.3)</p></td><td><p>0.413</p><p>(0.341, 0.500)</p><p>&lt;0.000001</p></td></tr><tr><td style="vertical-align:top"><p>Overall survival</p></td><td style="vertical-align:top"><p>148 (15.5%)</p></td><td style="vertical-align:top"><p>106 (19.1%)</p></td><td style="vertical-align:top"><p>NR</p><p>(56.1, NR)</p></td><td style="vertical-align:top"><p>NR</p><p>(46.9, NR)</p></td><td><p>0.685</p><p>(0.533, 0.881)</p><p>0.003048</p></td></tr><tr><td style="vertical-align:top"><p>Time to pain progression<sup>c, d</sup></p></td><td style="vertical-align:top"><p>251 (26.3%)</p></td><td style="vertical-align:top"><p>178 (32.1%)</p></td><td style="vertical-align:top"><p>40.3</p><p>(33.2, 41.2)</p></td><td style="vertical-align:top"><p>25.4</p><p>(19.1, 29.6)</p></td><td><p>0.647</p><p>(0.533, 0.785)</p><p>0.000008</p></td></tr><tr><td style="vertical-align:top"><p>Time to initiation of first cytotoxic chemotherapy</p></td><td style="vertical-align:top"><p>127 (13.3%)</p></td><td style="vertical-align:top"><p>98 (17.7%)</p></td><td style="vertical-align:top"><p>NR</p><p>(NR, NR)</p></td><td style="vertical-align:top"><p>NR</p><p>(NR, NR)</p></td><td style="vertical-align:top"><p>0.579</p><p>(0.444, 0.755)</p><p>0.000044</p></td></tr><tr><td style="vertical-align:top"><p>Time to first symptomatic skeletal event</p></td><td style="vertical-align:top"><p>29 (3.0%)</p></td><td style="vertical-align:top"><p>28 (5.1%)</p></td><td style="vertical-align:top"><p>NR</p><p>(NR, NR)</p></td><td style="vertical-align:top"><p>NR</p><p>(NR, NR)</p></td><td><p>0.484</p><p>(0.287, 0.815)</p><p>0.005294</p></td></tr></tbody></table><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; including 170&nbsp;patients who crossed over to open‑label darolutamide</p><p><sup>b</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio &lt;&nbsp;1 favours darolutamide</p><p><sup>c</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for MFS and time to pain progression, the analysis performed at the time of primary completion is considered as the final analysis</p><p><sup>d&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Patient reported outcome as evaluated by Brief Pain Inventory‑Short Form questionnaire</p><p>NR:&nbsp;&nbsp;&nbsp;&nbsp; Not reached.</p><p>&nbsp;</p><p>Treatment with darolutamide resulted in a longer progression free survival (PFS, median 36.8&nbsp;vs 14.8&nbsp;months, HR=0.380, nominal p&lt;0.000001) and time to PSA progression (median 29.5&nbsp;vs 7.2&nbsp;months, HR=0.164, nominal p&lt;0.000001). Consistency of effect was observed across all measures of survival (MFS, OS and PFS).</p><p>&nbsp;</p><p><strong>Figure&nbsp;1: Kaplan‑Meier curves of metastasis free survival (ARAMIS)</strong></p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Textfeld_x0020_11" o:spid="_x0000_s1048" type="#_x0000_t202"
 style='position:absolute;margin-left:-77.1pt;margin-top:102.4pt;width:199.85pt;
 height:19.3pt;rotation:-90;z-index:251660288;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f" strokeweight=".5pt">
 <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top'>
  <![if RotText]><![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=center style='text-align:center'><b
    style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:6.0pt;
    mso-bidi-font-size:10.0pt;font-family:"Arial",sans-serif'>Metastasis Free
    Survival Probability (%)<o:p></o:p></span></b></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]><![endif]></v:textbox>
</v:shape><![endif]--><img width="29" height="269" alt="Text Box: Metastasis Free Survival Probability (%)" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shape
 id="Textfeld_x0020_10" o:spid="_x0000_s1047" type="#_x0000_t202" style='position:absolute;
 margin-left:-19.3pt;margin-top:235.7pt;width:68.35pt;height:31.3pt;z-index:251658240;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f" strokeweight=".5pt"/><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Darolutamide</strong></p><p><strong>Placebo</strong></p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:group id="Gruppieren_x0020_3" o:spid="_x0000_s1043"
 style='position:absolute;margin-left:257.45pt;margin-top:8.6pt;width:121.9pt;
 height:28.35pt;z-index:251666432;mso-width-relative:margin;
 mso-height-relative:margin' coordsize="14729,3647" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Textfeld_x0020_4" o:spid="_x0000_s1044" type="#_x0000_t202"
  style='position:absolute;width:14729;height:3647;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQA5dTnqwwAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Bb8Iw
DIXvSPsPkZG4QQpI09QREGJioJ0Y2w/wGtNWNE5JMij8enxA4mbrPb/3ebboXKPOFGLt2cB4lIEi
LrytuTTw+7MevoGKCdli45kMXCnCYv7Sm2Fu/YW/6bxPpZIQjjkaqFJqc61jUZHDOPItsWgHHxwm
WUOpbcCLhLtGT7LsVTusWRoqbGlVUXHc/zsDuy39TT/XU7s5burD18etOF1DNGbQ75bvoBJ16Wl+
XG+t4Aus/CID6PkdAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEAOXU56sMAAADbAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
" filled="f" strokeweight=".5pt">
  <v:textbox inset="1.5mm,.3mm,1.5mm,.3mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='text-indent:.5in;line-height:11.0pt;mso-line-height-rule:
     exactly;tab-stops:.5in'><b style='mso-bidi-font-weight:normal'><span
     lang=EN-GB style='font-size:7.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>Darolutamide (N = 955)<o:p></o:p></span></b></p>
     <p class=MsoNormal style='line-height:11.0pt;mso-line-height-rule:exactly;
     tab-stops:.5in'><b style='mso-bidi-font-weight:normal'><span lang=EN-GB
     style='font-size:7.0pt;mso-bidi-font-size:9.0pt;font-family:"Arial",sans-serif'><span
     style='mso-spacerun:yes'>    </span><span style='mso-tab-count:1'>              </span>Placebo
     (N = 554)<o:p></o:p></span></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:line id="Gerade_x0020_Verbindung_x0020_14" o:spid="_x0000_s1045"
  style='position:absolute;visibility:visible;mso-wrap-style:square' from="954,1033"
  to="4338,1033" o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
"/>
 <v:line id="Gerade_x0020_Verbindung_x0020_16" o:spid="_x0000_s1046" style='position:absolute;
  visibility:visible;mso-wrap-style:square' from="1033,2146" to="4418,2146"
  o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
">
  <v:stroke dashstyle="dash"/>
 </v:line></v:group><![endif]--><img width="167" height="42" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image002.gif" /><!--[if gte vml 1]><v:shape
 id="Textfeld_x0020_13" o:spid="_x0000_s1042" type="#_x0000_t202" style='position:absolute;
 margin-left:33.35pt;margin-top:221.9pt;width:77.45pt;height:20.85pt;z-index:251664384;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:page;
 mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f" strokeweight=".5pt"/><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Patients at risk</strong></p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Textfeld_x0020_12" o:spid="_x0000_s1041"
 type="#_x0000_t202" style='position:absolute;margin-left:138.3pt;margin-top:221.8pt;
 width:156.25pt;height:24.35pt;z-index:251662336;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f" strokeweight=".5pt"/><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Months from Randomisation</strong></p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Grafik_x0020_2" o:spid="_x0000_i1027" type="#_x0000_t75"
 style='width:396.5pt;height:266.5pt;visibility:visible;mso-wrap-style:square'
 o:bordertopcolor="black" o:borderleftcolor="black" o:borderbottomcolor="black"
 o:borderrightcolor="black">
 <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image003.jpg"
  o:title="" croptop="1777f" cropbottom="4110f"/>
 <w:bordertop type="single" width="2"/>
 <w:borderleft type="single" width="2"/>
 <w:borderbottom type="single" width="2"/>
 <w:borderright type="single" width="2"/>
</v:shape><![endif]--><img width="530" height="357" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image004.jpg" /></p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Figure&nbsp;2: Kaplan‑Meier curves of overall survival </strong><strong>(ARAMIS)</strong></p><p><!--[if gte vml 1]><v:group
 id="Group_x0020_195" o:spid="_x0000_s1035" style='position:absolute;
 margin-left:15.4pt;margin-top:16.4pt;width:412.2pt;height:281.45pt;z-index:251668480'
 coordsize="52349,35747" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Text_x0020_Box_x0020_120" o:spid="_x0000_s1036" type="#_x0000_t202"
  style='position:absolute;left:24067;top:31309;width:12052;height:1200;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" stroked="f" strokecolor="black [3213]">
  <v:textbox inset=".5mm,0,.5mm,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b
     style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:
     6.0pt;mso-bidi-font-size:10.0pt;font-family:"Arial",sans-serif'>Months
     from Randomisation<o:p></o:p></span></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Text_x0020_Box_x0020_122" o:spid="_x0000_s1037" type="#_x0000_t202"
  style='position:absolute;top:33284;width:5835;height:2463;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
  <v:textbox inset=".5mm,0,.5mm,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=right style='margin-bottom:2.0pt;text-align:right;
     line-height:normal'><b style='mso-bidi-font-weight:normal'><span
     lang=EN-GB style='font-size:6.0pt;mso-bidi-font-size:10.0pt;font-family:
     "Arial",sans-serif'>Darolutamide<o:p></o:p></span></b></p>
     <p class=MsoNormal align=right style='text-align:right;line-height:normal'><b
     style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:
     6.0pt;mso-bidi-font-size:10.0pt;font-family:"Arial",sans-serif'>Placebo<o:p></o:p></span></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Text_x0020_Box_x0020_121" o:spid="_x0000_s1038" type="#_x0000_t202"
  style='position:absolute;left:6583;top:31674;width:15316;height:1200;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" stroked="f" strokecolor="white [3212]">
  <v:textbox inset=".5mm,0,.5mm,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='line-height:normal'><b style='mso-bidi-font-weight:
     normal'><span lang=EN-GB style='font-size:6.0pt;mso-bidi-font-size:10.0pt;
     font-family:"Arial",sans-serif'>Patients at risk<o:p></o:p></span></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="Text_x0020_Box_x0020_123" o:spid="_x0000_s1039" type="#_x0000_t202"
  style='position:absolute;left:2121;top:7680;width:2165;height:13050;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" stroked="f">
  <v:textbox style='layout-flow:vertical;mso-layout-flow-alt:bottom-to-top'
   inset=".5mm,0,.5mm,0">
   <![if RotText]><![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal align=center style='text-align:center;line-height:normal'><b
     style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:
     6.0pt;mso-bidi-font-size:10.0pt;font-family:"Arial",sans-serif'>Overall
     Survival Probability (%)<o:p></o:p></span></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]><![endif]></v:textbox>
 </v:shape><v:shape id="Textfeld_x0020_27" o:spid="_x0000_s1040" type="#_x0000_t202"
  style='position:absolute;left:36868;width:15481;height:3600;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" strokeweight=".5pt">
  <v:textbox inset="1.5mm,.3mm,1.5mm,.3mm">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='text-indent:.5in;line-height:11.0pt;mso-line-height-rule:
     exactly;tab-stops:.5in'><b style='mso-bidi-font-weight:normal'><span
     lang=EN-GB style='font-size:7.0pt;mso-bidi-font-size:9.0pt;font-family:
     "Arial",sans-serif'>Darolutamide (N = 955)<o:p></o:p></span></b></p>
     <p class=MsoNormal style='line-height:11.0pt;mso-line-height-rule:exactly;
     tab-stops:.5in'><b style='mso-bidi-font-weight:normal'><span lang=EN-GB
     style='font-size:7.0pt;mso-bidi-font-size:9.0pt;font-family:"Arial",sans-serif'><span
     style='mso-spacerun:yes'>    </span><span style='mso-tab-count:1'>              </span>Placebo
     (N = 554)<o:p></o:p></span></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape></v:group><![endif]--><img width="25" height="140" alt="Text Box: Overall Survival Probability (%)" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image005.gif" /><img width="553" height="378" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image006.gif" /><!--[if gte vml 1]><v:shape
 id="Picture_x0020_3" o:spid="_x0000_i1026" type="#_x0000_t75" style='width:453.5pt;
 height:305pt;visibility:visible;mso-wrap-style:square' o:bordertopcolor="#ff7f00 pure"
 o:borderleftcolor="#ff7f00 pure" o:borderbottomcolor="#ff7f00 pure"
 o:borderrightcolor="#ff7f00 pure">
 <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image007.png"
  o:title=""/>
 <w:bordertop type="single" width="6"/>
 <w:borderleft type="single" width="6"/>
 <w:borderbottom type="single" width="6"/>
 <w:borderright type="single" width="6"/>
</v:shape><![endif]--><img width="606" height="408" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image008.gif" /><!--[if gte vml 1]><v:line id="Straight_x0020_Connector_x0020_193"
 o:spid="_x0000_s1034" style='position:absolute;z-index:251670528;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text' from="312.15pt,23.75pt"
 to="334.05pt,23.75pt" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" strokecolor="black [3213]">
 <v:stroke joinstyle="miter"/>
</v:line><![endif]--><img width="31" height="1" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image009.gif" /><!--[if gte vml 1]><v:line
 id="Straight_x0020_Connector_x0020_194" o:spid="_x0000_s1033" style='position:absolute;
 z-index:251672576;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-width-relative:margin' from="312.45pt,35.8pt" to="334.35pt,35.8pt"
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" strokecolor="black [3213]">
 <v:stroke dashstyle="dash" joinstyle="miter"/>
</v:line><![endif]--><img width="31" height="2" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image010.gif" /></p><p>&nbsp;</p><p>Patients receiving darolutamide in the ARAMIS study (double‑blind period) demonstrated a significantly higher confirmed PSA response rate (defined as a &ge;&nbsp;50% reduction from baseline), compared with patients receiving placebo, 84.0% vs 7.9% (difference&nbsp;=&nbsp;76.1%, p&lt;0.000001 (nominal p‑value, for information only)).</p><p>&nbsp;</p><p><em>metastatic hormone‑sensitive prostate cancer (mHSPC)</em></p><p>The efficacy and safety of darolutamide in combination with docetaxel was assessed in a multicentre, double‑blind, placebo‑controlled phase&nbsp;III&nbsp;study (ARASENS) in patients with mHSPC. In total, 1306&nbsp;patients were randomised 1:1 to receive 600&nbsp;mg darolutamide orally twice daily (n=651) or matching placebo (n=655), concomitantly with 75&nbsp;mg/m<sup>2</sup> of docetaxel for 6&nbsp;cycles. Treatment with darolutamide or placebo continued until symptomatic progressive disease, change of antineoplastic therapy, unacceptable toxicity, death, or withdrawal.</p><p>&nbsp;</p><p>Presence of metastasis was assessed by independent central radiological review. Patients with regional lymph node involvement only (M0) were excluded from the study. Randomisation was stratified by extent of disease (non‑regional lymph nodes metastases only (M1a), bone metastases with or without lymph node metastases (M1b) or visceral metastases with or without lymph node metastases or with or without bone metastases (M1c)) and by alkaline phosphatase level (&lt;&nbsp;or&nbsp;&ge; upper limit of normal) at study entry. Patients with brain metastases were allowed to enter the study but there were no patients with brain metastasis enrolled.</p><p>&nbsp;</p><p>The following patient demographics and disease characteristics were balanced between treatment arms. The median age was 67&nbsp;years (range 41‑89) and 0.5% of patients were 85&nbsp;years of age or older. The racial distribution was 52% White, 36% Asian, and 4% Black. A majority of patients had a Gleason score of 8 or higher at diagnosis (78%). 71% of patients had an ECOG&nbsp;PS score of 0 and 29% of patients had an ECOG&nbsp;PS score of 1. There were 86.1% of patients with <em>de novo</em> and 12.9% of patients with recurrent disease. At study entry 3% of patients had M1a, 79.5% had M1b and 17.5% had M1c; alkaline phosphatase was &lt;&nbsp;ULN in 44.5% of patients and &ge;&nbsp;ULN in 55.5% of patients; median PSA level at baseline was 30.3&nbsp;&micro;g/L and 24.2&nbsp;&micro;g/L for darolutamide vs the placebo group, respectively. Patients with a medical history of seizure were allowed to enter the study, and 4&nbsp;patients (0.6%) were enrolled in the darolutamide+docetaxel arm.</p><p>&nbsp;</p><p>77.0% of patients had high‑volume disease and 23.0% had low‑volume disease. High‑volume disease was defined as presence of visceral metastases or 4&nbsp;or more bone lesions, with at least&nbsp;1 metastasis beyond the vertebral column and pelvic bones. Around 25% of patients received concomitant treatment with bisphosphonates or denosumab.</p><p>&nbsp;</p><p>The primary efficacy endpoint was overall survival (OS). Secondary endpoints were time to castration‑resistant prostate cancer, time to pain progression, symptomatic skeletal event free survival (SSE‑FS), time to first symptomatic skeletal event (SSE), time to initiation of subsequent antineoplastic therapy, time to worsening of disease‑related physical symptoms, and time to initiation of opioid use for &ge;&nbsp;7 consecutive days. Pain progression was assessed using the patient‑reported outcome (PROs) Brief Pain Inventory‑Short Form (BPI-SF), defined as at least a 2‑point worsening from nadir, and initiation of short‑ or long‑acting opioid use for pain for &ge;7&nbsp;consecutive days.</p><p>&nbsp;</p><p>The median duration of treatment was 41.0&nbsp;months (range: 0.1&nbsp;to&nbsp;56.5&nbsp;months) in patients treated with darolutamide+docetaxel and 16.7&nbsp;months (range: 0.3&nbsp;to&nbsp;55.8&nbsp;months) in patients treated with placebo+docetaxel. 87.6% and 85.5% of patients received full 6&nbsp;cycles of docetaxel and 1.5% and 2.0% of patients did not receive docetaxel in darolutamide+docetaxel and placebo+docetaxel arm, respectively.</p><p>&nbsp;</p><p><strong>Table&nbsp;4: Efficacy results from the ARASENS study</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:596px"><tbody><tr><td rowspan="2"><p><strong>Efficacy parameter</strong></p></td><td colspan="2"><p><strong>Number (%) of patients with events</strong></p></td><td colspan="2"><p><strong>Median (months) (95%&nbsp;CI)</strong></p></td><td rowspan="2"><p><strong>Hazard Ratio</strong><sup>b</sup></p><p><strong>(95%&nbsp;Confidence Interval [CI])</strong></p><p><strong>p‑value</strong></p><p><strong>(one‑sided)</strong><sup>c</sup></p></td></tr><tr><td><p><strong>Darolutamide + docetaxel</strong></p><p><strong>(N=651)</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>+ docetaxel</strong></p><p><strong>(N=654)</strong><sup>a</sup></p></td><td><p><strong>Darolutamide</strong></p><p><strong>+ docetaxel</strong></p><p><strong>(N=651)</strong></p></td><td><p><strong>Placebo</strong></p><p><strong>+ docetaxel</strong></p><p><strong>(N=654)</strong><sup>a</sup></p></td></tr><tr><td style="vertical-align:top"><p>Overall survival<sup>d</sup></p></td><td style="vertical-align:top"><p>229 (35.2%)</p></td><td style="vertical-align:top"><p>304 (46.5%)</p></td><td style="vertical-align:top"><p>NR</p><p>(NR, NR)</p></td><td style="vertical-align:top"><p>48.9</p><p>(44.4, NR)</p></td><td style="vertical-align:top"><p>0.675</p><p>(0.568, 0.801)</p><p>&lt;0.0001</p></td></tr></tbody></table><p><sup>a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>one patient in placebo arm was excluded from all analyses</p><p><sup>b&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>Hazard ratio &lt;&nbsp;1 favours darolutamide</p><p><sup>c&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>based on stratified log‑rank test</p><p><sup>d&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </sup>OS results were consistent across patient subgroups, including extent of disease and alkaline phosphatase levels</p><p>NR: not reached</p><p>&nbsp;</p><p>The following secondary efficacy endpoints showed a statistically significant advantage in favour of the patients in the darolutamide+docetaxel arm compared to patients in the placebo+docetaxel arm: time to castration‑resistant prostate cancer (median NR vs 19.1&nbsp;months; HR=0.357, p&lt;0.0001); time to first symptomatic skeletal event (median NR vs NR months; HR=0.712, p=0.0081); time to initiation of subsequent antineoplastic chemotherapy (median NR vs 25.3&nbsp;months; HR=0.388, p&lt;0.0001); time to pain progression (median NR vs 27.5&nbsp;months; HR=0.792, p=0.0058); symptomatic skeletal event free survival time (median 51.2&nbsp;vs 39.7&nbsp;months; HR=0.609, p&lt;0.0001).</p><p>&nbsp;</p><p><strong>Figure&nbsp;3: Kaplan‑Meier curves of overall survival </strong><strong>(ARASENS)</strong><sup>a</sup></p><p><!--[if gte vml 1]><v:shape
 id="Textfeld_x0020_16" o:spid="_x0000_s1032" type="#_x0000_t202" style='position:absolute;
 margin-left:28.95pt;margin-top:271.05pt;width:88.9pt;height:15pt;z-index:251676672;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-width-relative:margin;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAarH4vH8DAADaCAAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWy0Vttu2zgQfV+g/0DwvbV8ibcxqhRO
dhMsEKSGnaLPE4qyhFAkl2Qcu1/fQ0qyXbdo0RsCx0PO4XDmzIV+83bbKLaRztdG53z4KuNMamGK
Wq9z/v7++uVrznwgXZAyWuZ8Jz1/e/Hirzc0WzuyVS0YLGg/o5xXIdjZYOBFJRvyr4yVGrrSuIYC
lm49KBw9w3KjBqMsmw4aqjW/OJj6hwKxJ1f/hCllxKMsrkhvyMOkErPjnc5HJX7dMs305sbZlV24
6Lm42ywcq4ucgzlNDSjig07RwbAcnJxaHwxsS9dEvClLtkUGRtPX2fkZZ7ucT8aj0WRy1tqT28BE
BAxH59kYlwkghufZWZZ1F1bvvmNCVP9+2wjcbN2BcOSit9FBvfky5sk+6Hv4V0pVsOF0H3/Es7C9
NNHtuJto6K34jsHfRMDed5pZ58ONNA2LQs6dFCFVGW1ufWjd6CEpMHNdK5WSpjR7zvl0fJalA7rX
wLjSESvLEtb2ZvoYwnaVOIrBFrsIfMA3oncGDoAkb8V1DW9uyYcFOTQLNtF24R3+lcrgVqFqy1ll
3MfTvYhD4ULD2TOaLuf+/ydykjP1n/bJVOgF1wsPvaCfmiujYgaiF0nE3S6oXiydaT4YV8zjLVCR
Frgr56EXrwJWUKCThZzPkyxMYync6pVFTw0TW5HT++0HcrYjPqAm7syqIiu/xn+LTVXRshV5Uz6s
wk7JlI7EaSyihtxtuhbCMgoJGi+PAsJaBM82FKMct/2QMnbQX8ryFJnaBjCcPmjnZfgGrtMGekAF
RBwkZg1SMJ5mGTqVkVpjjKqu2HsgbumK3cVTDhEpigNW6pc3l8jLx5z/Db/ZQ8/lcZ2BFAq1ZmFn
ZUkCE2bualKcWdLGY5mNsstsmk3w3f9NoK2DqK6pqRUGxRgboiLnZcpxYlfSkcn7upGe3clntjQN
6c+Mj2B8jEEzwWcE6dT4EG/E58YRMIJMDF0s4LzUyA8F5mr/GKcAyIuQCJC6iA2xPObk/arlZDgE
KQl01HZf0vF7fYdLf5SYQ8CJBNR4JGQ/OJ68XNklhkw7qPrJ4mNTRCqUXsoSDw5mastNem7llXJt
A5AQYLsftwkdj5UYcT9ysMMfyP+Rw2314kS62eiwP9zU2riU0hO3i8fe5bLFJ1q6qEFQfIMGJ696
gnS/QuJPh+P1xScAAAD//wMAUEsDBBQABgAIAAAAIQCSfYfgHQcAAEkgAAAaAAAAY2xpcGJvYXJk
L3RoZW1lL3RoZW1lMS54bWzsWUtvGzcQvhfof1jsvbFkvWIjcmDJctzEL0RKihwpidplzF0uSMqO
bkVy6qVAgbTooQF666EoGqABGvTSH2PAQZv+iA65L1Ki4gdcIChsAcbu7DfD4czszOzwzt1nEfWO
MReExW2/eqviezgesTGJg7b/aLD92W3fExLFY0RZjNv+DAv/7sann9xB6yNKkiFDfDwIcYQ9EBSL
ddT2QymT9ZUVMQIyErdYgmN4NmE8QhJuebAy5ugEFojoymql0lyJEIn9DZAolaAehX+xFIoworyv
xGAvRhGsfjCZkBHW2PFRVSHETHQp944Rbfsgc8xOBviZ9D2KhIQHbb+i//yVjTsraD1jonIJr8G3
rf8yvoxhfLSq1+TBsFi0Xm/Um5uFfA2gchHXa/WavWYhTwPQaAQ7TXWxZbZWu/UMa4DSS4fsrdZW
rWrhDfm1BZ03G+pn4TUolV9fwG9vd8GKFl6DUnxjAd/orHW2bPkalOKbC/hWZXOr3rLka1BISXy0
gK40mrVuvtsCMmF0xwlfa9S3W6uZ8BIF0VBEl1piwmK5LNYi9JTxbQAoIEWSxJ6cJXiCRhCTXUTJ
kBNvlwQhBF6CYiaAXFmtbFdq8F/96vpKexStY2RwK71AE7FAUvp4YsRJItv+fZDqG5Czt29Pn785
ff776YsXp89/zdbWoiy+HRQHJt/7n77559WX3t+//fj+5bfp0vN4YeLf/fLVuz/+/JB42HFpirPv
Xr978/rs+6//+vmlQ/omR0MTPiARFt4+PvEesgg26NAfD/nlOAYhIibHZhwIFCO1ikN+T4YWen+G
KHLgOti242MOqcYFvDd9aincD/lUEofEB2FkAfcYox3GnVZ4oNYyzDyYxoF7cT41cQ8ROnat3UWx
5eXeNIEcS1wiuyG21DykKJYowDGWnnrGjjB27O4JIZZd98iIM8Em0ntCvA4iTpMMyNCKppJph0Tg
l5lLQfC3ZZu9x16HUdeut/CxjYR3A1GH8gNMLTPeQ1OJIpfIAYqoafBdJEOXkv0ZH5m4npDg6QBT
5vXGWAgXzwGH/RpOfwBpxu32PTqLbCSX5MglcxcxZiK32FE3RFHiwvZJHJrYz8URhCjyDpl0wfeY
/Yaoe/ADipe6+zHBlrvPzwaPIMOaKpUBop5MucOX9zCz4rc/oxOEXalmk0dWit3kxBkdnWlghfYu
xhSdoDHG3qPPHRp0WGLZvFT6fghZZQe7Aus+smNV3cdYYE83N4t5cpcIK2T7OGBL9NmbzSWeGYoj
xJdJ3gevmzbvQamLXAFwQEdHJnCfQL8H8eI0yoEAGUZwL5V6GCKrgKl74Y7XGbf8d5F3DN7Lp5Ya
F3gvgQdfmgcSu8nzQdsMELUWKANmgKDLcKVbYLHcX7Ko4qrZpk6+if3Slm6A7shqeiISn9sBzfU+
jf+u94EO4+yHV46X7Xr6HbdgK1ldstNZlkx25vqbZbj5rqbL+Jh8/E3NFprGhxjqyGLGuulpbnoa
/3/f0yx7n286mWX9xk0n40OHcdPJZMOV6+lkyuYF+ho18EgHPXrsEy2d+kwIpX05o3hX6MGPgO+Z
8TYQFZ+ebuJiCpiEcKnKHCxg4QKONI/HmfyCyLAfogSmQ1VfCQlEJjoQXsIEDI002Slb4ek02mPj
dNhZrarBZlpZBZIlvdIo6DCokim62SoHeIV4rW2gB625Aor3MkoYi9lK1BxKtHKiMpIe64LRHEro
nV2LFmsOLW4r8bmrFrQA1QqvwAe3B5/pbb9RBxZggnkcNOdj5afU1bl3tTOv09PLjGlFADTYeQSU
nl5Tui7dntpdGmoX8LSlhBFuthLaMrrBEyF8BmfRqagXUeOyvl4rXWqpp0yh14PQKtVo3f6QFlf1
NfDN5wYam5mCxt5J22/WGhAyI5S0/QkMjeEySiB2hPrmQjSA45aR5OkLf5XMknAht5AIU4PrpJNm
g4hIzD1Koravtl+4gcY6h2jdqquQED5a5dYgrXxsyoHTbSfjyQSPpOl2g6Isnd5Chk9zhfOpZr86
WHGyKbi7H45PvCGd8ocIQqzRqioDjomAs4Nqas0xgcOwIpGV8TdXmLK0a55G6RhK6YgmIcoqipnM
U7hO5YU6+q6wgXGX7RkMapgkK4TDQBVY06hWNS2qRqrD0qp7PpOynJE0y5ppZRVVNd1ZzFohLwNz
trxakTe0yk0MOc2s8Gnqnk+5a3mum+sTiioBBi/s56i6FygIhmrlYpZqSuPFNKxydka1a0e+wXNU
u0iRMLJ+Mxc7Z7eiRjiXA+KVKj/wzUctkCZ5X6kt7TrY3kOJNwyqbR8Ol2E4+Ayu4HjaB9qqoq0q
GlzBmTOUi/SguO1nFzkFnqeUAlPLKbUcU88p9ZzSyCmNnNLMKU3f0yeqcIqvDlN9Lz8whRqWHbBm
vYV9+r/xLwAAAP//AwBQSwMEFAAGAAgAAAAhAJxmRkG7AAAAJAEAACoAAABjbGlwYm9hcmQvZHJh
d2luZ3MvX3JlbHMvZHJhd2luZzEueG1sLnJlbHOEj80KwjAQhO+C7xD2btJ6EJEmvYjQq9QHCMk2
LTY/JFHs2xvoRUHwsjCz7DezTfuyM3liTJN3HGpaAUGnvJ6c4XDrL7sjkJSl03L2DjksmKAV201z
xVnmcpTGKSRSKC5xGHMOJ8aSGtHKRH1AVzaDj1bmIqNhQaq7NMj2VXVg8ZMB4otJOs0hdroG0i+h
JP9n+2GYFJ69elh0+UcEy6UXFqCMBjMHSldnnTUtXYGJhn39Jt4AAAD//wMAUEsBAi0AFAAGAAgA
AAAhALvlSJQFAQAAHgIAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwEC
LQAUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAAAAAAAAAAAAAAA2AQAAX3JlbHMvLnJlbHNQSwEC
LQAUAAYACAAAACEAarH4vH8DAADaCAAAHwAAAAAAAAAAAAAAAAAgAgAAY2xpcGJvYXJkL2RyYXdp
bmdzL2RyYXdpbmcxLnhtbFBLAQItABQABgAIAAAAIQCSfYfgHQcAAEkgAAAaAAAAAAAAAAAAAAAA
ANwFAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbFBLAQItABQABgAIAAAAIQCcZkZBuwAAACQB
AAAqAAAAAAAAAAAAAAAAADENAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEueG1s
LnJlbHNQSwUGAAAAAAUABQBnAQAANA4AAAAA
" filled="f" stroked="f" strokeweight=".5pt">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Patients at risk</strong></p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Textfeld_x0020_15" o:spid="_x0000_s1031"
 type="#_x0000_t202" style='position:absolute;margin-left:158.9pt;margin-top:265.15pt;
 width:151.5pt;height:14.95pt;z-index:251674624;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f" strokeweight=".25pt">
 <v:textbox inset="0,0,0,0"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>Months from Randomization</strong></p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:group id="Gruppieren_x0020_6" o:spid="_x0000_s1027"
 style='position:absolute;margin-left:49.3pt;margin-top:204.75pt;width:164.4pt;
 height:34pt;z-index:251680768;mso-width-relative:margin;mso-height-relative:margin'
 coordorigin="280,285" coordsize="14791,2218" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:shape id="Textfeld_x0020_8" o:spid="_x0000_s1028" type="#_x0000_t202"
  style='position:absolute;left:280;top:285;width:14792;height:2218;
  visibility:visible;mso-wrap-style:square;v-text-anchor:middle' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" strokeweight=".5pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal style='text-indent:35.4pt'><b style='mso-bidi-font-weight:
     normal'><span lang=PT style='font-size:7.0pt;mso-bidi-font-size:9.0pt;
     font-family:"Arial",sans-serif;mso-ansi-language:PT'>1 -
     Darolutamide+docetaxel (N = 651)<o:p></o:p></span></b></p>
     <p class=MsoNormal style='margin-left:35.45pt;text-indent:-35.45pt;
     tab-stops:.5in'><b style='mso-bidi-font-weight:normal'><span lang=PT
     style='font-size:7.0pt;mso-bidi-font-size:9.0pt;font-family:"Arial",sans-serif;
     mso-ansi-language:PT'><span style='mso-tab-count:1'>                  </span>2
     - Placebo+docetaxel (N = 654)<o:p></o:p></span></b></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:line id="Gerade_x0020_Verbindung_x0020_13" o:spid="_x0000_s1029"
  style='position:absolute;visibility:visible;mso-wrap-style:square' from="954,1033"
  to="2739,1033" o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" strokecolor="black [3213]">
  <v:stroke joinstyle="miter"/>
 </v:line><v:line id="Gerade_x0020_Verbindung_x0020_14" o:spid="_x0000_s1030"
  style='position:absolute;visibility:visible;mso-wrap-style:square' from="1033,1860"
  to="2819,1860" o:connectortype="straight" o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" strokecolor="black [3213]" strokeweight=".5pt">
  <v:stroke dashstyle="dash" joinstyle="miter"/>
 </v:line></v:group><![endif]--><img width="223" height="49" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image011.gif" /><!--[if gte vml 1]><v:shape
 id="Textfeld_x0020_18" o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
 margin-left:-89.2pt;margin-top:119.15pt;width:195.95pt;height:18.75pt;
 rotation:-90;z-index:251678720;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f" strokeweight=".5pt">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=center style='text-align:center'><b
    style='mso-bidi-font-weight:normal'><span lang=EN-GB style='font-size:8.0pt;
    mso-bidi-font-size:12.0pt;font-family:"Arial",sans-serif'>Overall Survival
    Probability (%)<o:p></o:p></span></b></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><![endif]--><img width="27" height="264" alt="Text Box: Overall Survival Probability (%)" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image012.gif" /><!--[if gte vml 1]><v:shape
 id="Picture_x0020_49" o:spid="_x0000_i1025" type="#_x0000_t75" alt="Chart&#10;&#10;Description automatically generated"
 style='width:453.5pt;height:315.5pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image013.png"
  o:title="Chart&#10;&#10;Description automatically generated" cropbottom="4713f"/>
</v:shape><![endif]--><img width="605" height="421" alt="Chart

Description automatically generated" src="file:///C:/Users/GOIYW/AppData/Local/Temp/msohtmlclip1/01/clip_image014.gif" /></p><p>&nbsp;</p><p><sup>a</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OS rate at 36&nbsp;months was 72.3% (95% CI, 68.8 to 75.8) in the darolutamide+docetaxel arm vs 63.8% (95% CI, 60.1 to 67.6) in the placebo+docetaxel arm.</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; OS rate at 48&nbsp;months was 62.7% (95% CI, 58.7 to 66.7) in the darolutamide+docetaxel arm vs 50.4% (95% CI, 46.3 to 54.6) in the placebo+docetaxel arm.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with darolutamide in all subsets of the paediatric population in prostate malignant neoplasms (see section&nbsp;4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>General introduction</u></p><p>&nbsp;</p><p>Darolutamide consists of two diastereomers [(<em>S</em>,<em>R</em>)‑darolutamide and (<em>S</em>,<em>S</em>)‑darolutamide] which interconvert via the main circulating metabolite called keto‑darolutamide. <em>In vitro</em>, all three substances show similar pharmacological activity. Darolutamide is poorly soluble in aqueous solvents over a large pH range and generally more soluble in organic solvents.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>Following oral administration of 600&nbsp;mg (2&nbsp;tablets of 300&nbsp;mg) twice daily, peak plasma concentrations of darolutamide at steady state were 4.79&nbsp;mg/L (coefficient of variation:&nbsp;30.9%) in nmCRPC patients in the ARAMIS study and 3.84&nbsp;mg/L (coefficient of variation:&nbsp;35.6%) in mHSPC patients in the ARASENS study. Median time to achieve peak plasma concentrations was 3&nbsp;to&nbsp;4&nbsp;hours. The ratio of the two diastereomers, (<em>S</em>,<em>R</em>)‑darolutamide to (<em>S</em>,<em>S</em>)‑darolutamide, changed from a 1:1 ratio in the tablet to an approximately 1:9 ratio in plasma based on AUC<sub>0‑12</sub> data at steady‑state. Following oral administration together with food, steady‑state is reached after 2‑5&nbsp;days of repeated twice‑daily dosing.</p><p>The absolute bioavailability compared to an intravenous injection is approximately 30% following oral administration of a NUBEQA tablet containing 300&nbsp;mg darolutamide under fasted conditions. Bioavailability of darolutamide was enhanced by 2.0‑ to 2.5‑fold when administered with food. A similar increase of exposure was observed for the major metabolite keto‑darolutamide.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The apparent volume of distribution of darolutamide after intravenous administration is 119&nbsp;L indicating that darolutamide is widely distributed throughout the body to both intracellular and extracellular fluid spaces.</p><p>Darolutamide is moderately (92%) bound to human plasma proteins without any difference between the two diastereomers. The major metabolite of darolutamide, keto‑darolutamide, is highly (99.8%) bound to plasma proteins.</p><p>Passage of darolutamide across the blood‑brain barrier has not been studied clinically. However, brain exposures to darolutamide in terms of AUC<sub>0‑24</sub> are very low with 4.5% of plasma exposure after single dose in rats and 1.9‑3.9% after repeated dose in mice. This indicates low passage of darolutamide across the intact blood‑brain barrier in rats and mice and a low likelihood that darolutamide crosses the intact blood‑brain barrier in humans to a clinically relevant extent.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>The diastereomers (<em>S</em>,<em>R</em>)‑darolutamide and (<em>S</em>,<em>S</em>)‑darolutamide are able to interconvert via the metabolite keto‑darolutamide with a preference for (<em>S</em>,<em>S</em>)‑darolutamide.</p><p>Following single oral administration of 300&nbsp;mg<sup>14&nbsp;</sup>C‑darolutamide given as an oral solution, keto‑darolutamide is the only major metabolite with about 2‑fold higher total exposure in plasma compared to darolutamide. Darolutamide and keto‑darolutamide accounted together for 87.4% of the&nbsp;<sup>14&nbsp;</sup>C‑radioactivity in plasma indicating that all other metabolites are of minor importance.</p><p>Darolutamide is metabolised primarily by oxidative metabolism mediated mainly by CYP3A4, as well as by direct glucuronidation mediated preferentially by UGT1A9 and UGT1A1. In addition, mainly the AKR1C isoforms were shown to catalyse the reduction of keto‑darolutamide to the substance diastereomers.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>The effective half‑life of darolutamide and keto‑darolutamide in plasma of patients is approximately 18 to 20&nbsp;hours. Of the two diastereomers comprising darolutamide, (<em>S</em>,<em>R</em>)‑darolutamide has a shorter effective half‑life of 9&nbsp;hours compared to (<em>S</em>,<em>S</em>)‑darolutamide with an effective half‑life of 22&nbsp;hours. The clearance of darolutamide following intravenous administration was 116&nbsp;mL/min (CV:&nbsp;39.7%). A total of 63.4% of substance‑related material is excreted in the urine (approximately 7% unchanged), 32.4% is excreted in the faeces. More than 95% of the dose was recovered within 7&nbsp;days after administration.</p><p>&nbsp;</p><p><u>Linearity / Non‑linearity</u></p><p>&nbsp;</p><p>In the dose range of 100 to 700&nbsp;mg (after single dose and at steady state), the exposure to the two diastereomers and the major metabolite keto‑darolutamide increases linearly in a nearly dose‑related manner. Based on a saturated absorption, no further increase in exposure to darolutamide was observed at 900&nbsp;mg twice daily.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>No clinically relevant differences in the pharmacokinetics of darolutamide were observed (65‑95&nbsp;years).</p><p><u>&nbsp;</u></p><p><em>Renal impairment</em></p><p>In a clinical pharmacokinetic study, AUC and C<sub>max</sub> for darolutamide were 2.5 and 1.6‑fold higher in patients with severe renal impairment (estimated Glomerular Filtration Rate [eGFR] 15&nbsp;to 29&nbsp;mL/min/1.73 m<sup>2</sup>) compared to healthy volunteers.</p><p>A population pharmacokinetic analysis indicates a 1.1‑, 1.3‑ and an approximately 1.5‑fold higher exposure (AUC) of darolutamide in patients with mild, moderate and severe renal impairment (eGFR 15&nbsp;to 89&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>) compared to patients with normal renal function.</p><p>The pharmacokinetics of darolutamide has not been studied in patients with end‑stage renal disease receiving dialysis (eGFR&nbsp;&lt;&nbsp;15&nbsp;mL/min/1.73&nbsp;m<sup>2</sup>).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>In a clinical pharmacokinetic study, C<sub>max</sub> and AUC for darolutamide were 1.5 and 1.9‑fold higher in patients with moderate hepatic impairment (Child‑Pugh&nbsp;B) compared to healthy volunteers. There are no data for patients with severe hepatic impairment (Child‑Pugh&nbsp;C).</p><p>&nbsp;</p><p><em>Ethnic differences</em></p><p>No clinically relevant differences in the pharmacokinetics of darolutamide were observed based on ethnicity (White, Japanese, non‑Japanese Asian, Black or African American). A population pharmacokinetic analysis indicated a geometric mean increase in exposure (AUC) of up to 1.56‑fold (90% CI: 1.43 to 1.70) in Japanese patients compared to patients from all other regions in both the ARAMIS and ARASENS studies.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Systemic toxicity</u></p><p>&nbsp;</p><p>In repeated dose toxicity studies in rats and dogs, the main findings were changes in the male reproductive organs (decreases in organ weight with atrophy of the prostate and epididymides). These effects occurred at systemic exposures in the range of or below the anticipated human exposure (based on AUC comparison). Additional changes to reproductive tissues included minimal increase in vacuolation of the pituitary gland, atrophy and secretory reduction in seminal vesicles and mammary glands in rats as well as testicular hypospermia, seminiferous tubule dilatation and degeneration in dogs. Changes in the male reproductive organs in both species were consistent with the pharmacological activity of darolutamide and reversed or partially resolved after 4‑ to 8‑week recovery periods.</p><p>&nbsp;</p><p><u>Embryotoxicity / teratogenicity</u></p><p>&nbsp;</p><p>Studies on developmental toxicity have not been performed.</p><p>&nbsp;</p><p><u>Reproduction toxicity</u></p><p>&nbsp;</p><p>Studies on reproductive toxicity have not been performed. However, male fertility is likely to be impaired based on the findings in repeat‑dose toxicity studies in rats and dogs, which are consistent with the pharmacological activity of darolutamide.</p><p>&nbsp;</p><p><u>Genotoxicity and carcinogenicity</u></p><p>&nbsp;</p><p>Darolutamide did not induce mutations in the microbial mutagenesis (Ames) assay. At high concentrations, darolutamide did induce structural chromosome aberrations <em>in vitro</em> in cultured human lymphocytes. However, in the <em>in vivo</em> combined bone marrow micronucleus test and the Comet assay in the liver and duodenum of the rat, no genotoxicity was observed at exposures in excess of the maximum human exposure.</p><p>Oral administration of darolutamide to male rasH2 transgenic mice for 6&nbsp;months did not show carcinogenic potential at doses up to 1000&nbsp;mg/kg/day, which is 0.9‑1.3&nbsp;times for darolutamide and 2.1‑2.3&nbsp;times for keto‑darolutamide the clinical exposure (AUC) at the recommended clinical daily dose of 1200&nbsp;mg/day. Based on this study carcinogenic risk of darolutamide cannot be completely excluded.</p><p>&nbsp;</p><p><u>Safety pharmacology</u></p><p>&nbsp;</p><p><em>In vitro</em>, darolutamide weakly inhibited the hERG potassium current and the L‑type calcium channel. <em>In vivo</em>, in anaesthetised dogs, darolutamide slightly decreased the QT interval duration, but this effect was not found in conscious dogs.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core</u></p><p>Calcium hydrogen phosphate (E&nbsp;341)</p><p>Croscarmellose sodium</p><p>Lactose monohydrate</p><p>Magnesium stearate (E&nbsp;470b)</p><p>Povidone (E&nbsp;1201)</p><p>&nbsp;</p><p><u>Film‑coating</u></p><p>Hypromellose</p><p>Lactose monohydrate</p><p>Macrogol (E&nbsp;1521)</p><p>Titanium dioxide (E&nbsp;171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PVC/Aluminium foil blisters containing 16&nbsp;film‑coated tablets.</p><p>Each pack contains 96 or 112&nbsp;film‑coated tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer AG 
51368 Leverkusen
Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                02/2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>